Fortune Journals

Archives of Clinical and Medical Case Reports

ISSN: 2575-9655 Peer Reviewed Open Access
Submit Manuscript →

No Evidence of Cancer or Cancer Markers 3 Years After Receiving a Non-Reportable Cell-Free DNA Sequence Analysis During Pregnancy

Vol 9, Issue 4 Pages 137–139 Published: 15 Jul 2025
Jerome H. Check1,2,*
Article Information
Citation: Jerome H. Check. No Evidence of Cancer or Cancer Markers 3 Years After Receiving a Non-Reportable Cell-Free Dna Sequence Analysis During Pregnancy. Archives of Clinical and Medical Case Reports 9 (2025): 137-139.

DOI: 10.26502/acmcr.96550722

Share
Abstract
The blood test performed in pregnant women who are at least 10 weeks from conception that measures cell free DNA from the placenta that can detect fetal aneuploidy that could lead to live deliveries (especially for aneuploidies e.g., trisomy 13,18, and 21) is known as non-invasive prenatal testing (NIPT). When this test is not able to be interpreted, if there are no fetal anomalies present or benign tumors e.g., fibroids, researchers have found a high percentage of various cancers in these women. Even in the low percentage of women found who do not have obvious cancer at the present time, or a known non-malignant etiology for the uninterpretable NIPT, thereafter is the possibility that an occult cancer is present and will manifest shortly. Presented is a case where there is still no evidence of cancer 2 years post-partum despite an unreportable NIPT (x2).
Keywords

Cell free DNA, Non-invasive prenatal testing, Cancer, Fibroid tumors, Fetal anomalies.

Cell free DNA articles; Non-invasive prenatal testing articles; Cancer articles; Fibroid tumors articles; Fetal anomalies articles.
Article Details
1. Introduction
Article Views
795
Total Views
Download PDF
Article Details
  • Volume9
  • Issue4
  • Pages137–139
  • Published15 Jul 2025
  • ISSN2575-9655
  • DOI10.26502/acmcr.96550722
Journal

Archives of Clinical and Medical Case Reports

Impact Factor: 5.3
Submit Manuscript
© 2016–2026, Copyrights Fortune Journals. All Rights Reserved.